KalVista Pharmaceuticals (NASDAQ:KALV) Now Covered by TD Cowen

TD Cowen started coverage on shares of KalVista Pharmaceuticals (NASDAQ:KALV) in a research note issued to investors on Tuesday, MarketBeat reports. The brokerage issued a buy rating and a $30.00 price target on the specialty pharmaceutical company’s stock.

A number of other research analysts have also weighed in on KALV. Needham & Company LLC reissued a “buy” rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a report on Thursday, December 5th. Cantor Fitzgerald restated an “overweight” rating on shares of KalVista Pharmaceuticals in a research report on Monday, December 9th. Bank of America started coverage on KalVista Pharmaceuticals in a research note on Wednesday, December 18th. They set a “buy” rating and a $22.00 price objective on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a research note on Friday, December 6th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $25.00.

KalVista Pharmaceuticals Price Performance

Shares of KALV opened at $8.76 on Tuesday. The firm has a market cap of $432.90 million, a P/E ratio of -2.41 and a beta of 0.86. The company has a 50 day simple moving average of $9.56 and a two-hundred day simple moving average of $11.37. KalVista Pharmaceuticals has a 1 year low of $7.97 and a 1 year high of $16.88.

Insiders Place Their Bets

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 8,077 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $9.26, for a total value of $74,793.02. Following the transaction, the insider now owns 94,199 shares in the company, valued at $872,282.74. The trade was a 7.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Benjamin L. Palleiko sold 7,627 shares of the stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $9.75, for a total transaction of $74,363.25. Following the sale, the chief executive officer now directly owns 274,596 shares of the company’s stock, valued at approximately $2,677,311. The trade was a 2.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 32,291 shares of company stock worth $304,086 over the last 90 days. Company insiders own 10.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. lifted its position in KalVista Pharmaceuticals by 67.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company’s stock valued at $96,000 after acquiring an additional 3,328 shares during the last quarter. Intech Investment Management LLC acquired a new position in shares of KalVista Pharmaceuticals during the third quarter worth $126,000. SG Americas Securities LLC purchased a new stake in shares of KalVista Pharmaceuticals during the 3rd quarter valued at $153,000. Quest Partners LLC acquired a new stake in shares of KalVista Pharmaceuticals in the 3rd quarter worth $175,000. Finally, Evoke Wealth LLC purchased a new position in KalVista Pharmaceuticals during the 2nd quarter worth $181,000.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).